CKLIFE SCIENCES (00775) announced its interim results, reporting a loss attributable to shareholders of HK$28.73 million, a year-on-year decrease of 80.95%.

CKLIFE SCIENCES (00775) announced its interim results for 2026, reporting revenue of HK$2.716 billion, an increase of 4.22% year-on-year; the loss attributable to shareholders was HK$28.73 million, a decrease of 80.95% year-on-year; the loss per share was HK$0.03. In the second half of 2025, the company underwent a corporate restructuring to enhance research and development, introducing more expertise and technology to improve execution capabilities. This restructuring involved the acquisition of Polynoma, a subsidiary of CKLIFE SCIENCES engaged in research and development, by TransCode Therapeutics (RNAZ), a company listed on NASDAQ in the United States. According to the transaction arrangement, CKLIFE SCIENCES is expected to become a major shareholder of RNAZ. In the first half of 2026, since RNAZ shareholders had not yet approved the change in control, the related expenses of Polynoma and RNAZ were not included in the companys consolidated financial statements. This change in accounting treatment resulted in a significant reduction in research and development expenses during the review period, leading to a corresponding decrease in loss compared to the previous year.